A naturally occurring hormone can reverse obesity by hijacking the same brain circuits targeted by blockbuster weight loss drugs, according to new research from the University of Oklahoma. The findings open a different therapeutic pathway that may sidestep some of the side effects plaguing current medications.
The hormone, called FGF21, works by activating a chain of signals in the hindbrain, a lower region of the brain that controls metabolism and appetite. What makes this discovery surprising is that researchers expected to find activity in the hypothalamus, the brain region long thought to be the main controller of body weight. Instead, FGF21 acts on two hindbrain structures called the nucleus of the solitary tract and the area postrema, which then communicate with another structure known as the parabrachial nucleus.
"We thought we would find that it signaled to the hypothalamus, so we were very surprised to discover that the signal was to the hindbrain, which is where the GLP-1 analogs are believed to act," said Matthew Potthoff, the lead researcher and a professor of biochemistry and physiology at OU's College of Medicine.
The results, published in Cell Reports, matter because FGF21 and GLP-1 drugs operate through fundamentally different mechanisms even though they target overlapping brain regions. GLP-1 medications like semaglutide reduce appetite and food intake. FGF21 instead cranks up the body's metabolic rate, burning more energy without necessarily suppressing hunger.
That distinction could prove valuable. Current GLP-1 therapies come with gastrointestinal side effects and, in some patients, bone loss. A hormone-based approach that increases energy expenditure rather than suppressing appetite might avoid those complications.
FGF21 has already attracted pharmaceutical attention. Several companies are testing FGF21-based drugs in clinical trials for MASH, a serious liver disease marked by fat accumulation and dysfunction. The hormone's ability to improve metabolic health in the liver while also reducing body weight suggests it could address both conditions simultaneously.
Potthoff and his team mapped out exactly which brain circuits mediate FGF21's weight-loss effects in mice. This level of precision matters for drug design. "By identifying the specific circuit, it can help in the creation of more targeted therapies that are effective without negative side effects," Potthoff said.
The researchers acknowledged that additional studies are needed to determine whether the same hindbrain circuit that drives fat burning also explains FGF21's ability to reverse fatty liver disease. Still, the early evidence suggests this natural hormone could become the foundation for a new class of obesity and metabolic disease treatments.
Author Jessica Williams: "This could be the exit ramp from GLP-1 side effects everyone's been waiting for, assuming the hindbrain pathway translates cleanly to humans."
Comments